Abstract 5570
Background
De novo metastatic breast cancer (dnMBC) represents 6–10% of breast cancer. Due to its incurability, dnMBC is generally treated with systemic therapies to achieve disease control and reduce tumor-related symptoms. The need for radical loco-regional treatment and its consequent benefit in this setting remains still controversial. Meta-analysis of retrospective studies and prospective randomized studies did not report a clear survival benefit. The aim of this study was to analyze the impact of surgery to primary tumor (PT) in patients (pts) presenting with dnMBC.
Methods
Between Feb 2006-Oct 2015 we performed a retrospective chart review to 129 consecutive pts who attended our hospital with dnMBC. Descriptive, Kaplan-Meier and Cox regression analyses were carried out using SPSS version 23.0.
Results
A total of 129 pts. were analyzed. Median age was 68 years (range: 20-95), 59 pts (46%) had single organ metastasis, and their distribution according to the predominant site of disease was: skin/soft tissue 42 pts (33%), bone 87 pts (67%) and visceral 85 pts (66%). Surgery (S) of the PT was done in 32 pts (25%), 24 was radical procedures, 8 palliative and besides, 27 pts underwent axillary dissection. Initial S treatment was the choice for 29 pts. In the S group single organ disease was present in 66% vs 39% non-S group. Metastatic sites were: 50% vs 71% visceral, 44% vs 21% with bone metastasis in the S vs non-S group respectively. With a median follow-up of 2 years (SD 2.20), the 5-yr overall survival (OS) was 11.64% in the entire de novo MBC population, with a median OS of 36 m in the S-group vs 21 m. in the non-S-group (HR 1.46 p = 0.081). Subgroup analyses did not show a benefit of PT surgery in OS regardless of the number of metastasis and site of disease, and BC subtypes. The multi-adjusted HR for surgery was 0.14 (p = 0.188). The multivariate Cox regression analysis model included the site of disease (p = 0.971), the histopathologic grade (p = 0.876) and the hormone receptor status (p = 0.003).
Conclusions
In our series, surgical treatment of the primary tumor in patients with de novo metastatic breast cancer did not show a benefit in overall survival. Results of ongoing randomized trials are needed.
Clinical trial identification
Legal entity responsible for the study
Medical Oncology Service, Basurto University Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract